Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Leap Therapeutics Concludes Enrollment In The Randomized Controlled Part C Of Distinguish Study Of DKN-01 In Combination With BeiGene's Tislelizumab And Chemotherapy In Patients With Advanced Gastroesophageal Junction And Gastric Cancer

Author: Benzinga Newsdesk | January 02, 2024 08:03am

Posted In: LPTX